Lage, Maureen J <br/><br/>
Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.  [electronic resource] 

 -  Journal of medical economics  Sep 2013 
 - 1146-53 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.3111/13696998.2013.823868  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antibodies, Monoclonal, Humanized--economics<br/>Cohort Studies<br/>Confidence Intervals<br/>Contracts--economics<br/>Feasibility Studies<br/>Female<br/>Hospitalization--economics<br/>Humans<br/>Immunosuppressive Agents--economics<br/>Insurance Claim Review--economics<br/>Interferon-beta--economics<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--diagnosis<br/>Natalizumab<br/>Observation--methods<br/>Odds Ratio<br/>Outcome Assessment, Health Care--economics<br/>Poisson Distribution<br/>Predictive Value of Tests<br/>Prognosis<br/>Recurrence<br/>Retrospective Studies<br/>Risk Management<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult